CoChat

GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach

Open access
Wang, Jing-Yue, Wang, Quan-Wei, Yang, Xin-Yu, Yang, Wei, Li, Dong-Rui, Jin, Jing-Yu, Zhang, Hui-Cong, Zhang, Xian-Feng · 2023 · Frontiers in Endocrinology

The DOI matches its Crossref record; 143 of the 145 references it cites were found in a registry or an index; 12 of the 131 sources its claims cite were checked for support.

Abstract

Obesity is a complex disease characterized by excessive fat accumulation which is caused by genetic, environmental and other factors. In recent years, there has been an increase in the morbidity, disability rate,and mortality due to obesity, making it great threat to people’s health and lives, and increasing public health care expenses. Evidence from previous studies show that weight loss can significantly reduce the risk of obesity-related complications and chronic diseases. Diet control, moderate exercise, behavior modification programs, bariatric surgery and prescription drug treatment are the major interventions used to help people lose weight. Among them, anti-obesity drugs have high compliance rates and cause noticeable short-term effects in reducing obese levels. However, given the safety or effectiveness concerns of anti-obesity drugs, many of the currently used drugs have limited clinical use. Glucagon-like peptide-1 receptor (GLP-1R) agonists are a group of drugs that targets incretin hormone action, and its receptors are widely distributed in nerves, islets, heart, lung, skin, and other organs. Several animal experiments and clinical trials have demonstrated that GLP-1R agonists are more effective in treating or preventing obesity. Therefore, GLP-1R agonists are promising agents for the treatment of obese individuals. This review describes evidence from previous research on the effects of GLP-1R agonists on obesity. We anticipate that this review will generate data that will help biomedical researchers or clinical workers develop obesity treatments based on GLP-1R agonists.

Overview

CoChat Summary

TL;DR

This narrative review summarizes evidence that GLP-1 receptor agonists, including short-acting and long-acting agents, reduce body weight in obese and diabetic populations and are promising anti-obesity treatments. It also briefly covers dual/triple incretin agonists and calls for more long-term safety and efficacy data, especially in non-diabetic and non-Western populations.

Key findings

  • In the STEP1 trial, 1,961 non-diabetic adults with BMI ≥30 kg/m² or ≥27 kg/m² with weight-related comorbidities received semaglutide 2.4 mg weekly for 68 weeks and lost an average of 15.3 kg; 86.4% vs 31.5% achieved ≥5% weight loss, 69.1% vs 12.0% achieved ≥10%, and 50.5% vs 4.9% achieved ≥15% versus placebo.
  • In STEP2, adults with overweight/obesity and type 2 diabetes lost -6.9 kg (-7%) with semaglutide 1 mg and -9.7 kg (-9.6%) with semaglutide 2.4 mg weekly.
  • Liraglutide 3 mg daily produced average weight loss of 8.40 ± 7.3 kg over 56 weeks in 3,731 patients without type 2 diabetes; in another trial, liraglutide 1.2–3 mg daily gave 4.8–7.2 kg average weight loss versus 4.1 kg with orlistat.
  • Tirzepatide 5–15 mg per week reduced body weight by 5.4–11.7 kg in the SURPASS 1–5 trials in patients with type 2 diabetes.

Methods

  • Design: narrative review of GLP-1 receptor agonists for obesity treatment, including short-acting agents (beinaglutide, exenatide), once-daily agents (lixisenatide, liraglutide), once-weekly agents (semaglutide, dulaglutide, exenatide long-acting release, polyethylene glycol loxenatide), and dual/triple agonists.
  • Data: evidence from prior animal experiments and human clinical trials, including named programs such as STEP, AWARD, GetGoal, SCALE, and SURPASS; the review also includes a comparison table of anti-obesity drugs and schematic figures.
  • Analysis: narrative synthesis of cited studies, with no systematic search strategy, meta-analysis, or risk-of-bias assessment described.

Limitations

  • The paper states that the mechanism of GLP-1R in treating obesity is still uncertain and that more clinical evidence is needed for long-term safety and efficacy.
  • The paper states that except for liraglutide and semaglutide, there are few related clinical studies of other GLP-1R agonists, especially in obese or overweight people without diabetes.
  • The paper states that the race of patients in semaglutide-related clinical studies is relatively small and that more clinical trials in Asian and African obese populations are expected; evident from the text, the review is narrative rather than systematic and does not report formal quality assessment or publication-bias checks.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3389/fendo.2023.1085799

Cites

143 of 143 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Scheme 1 A schematic overview of GLP-1 receptor agonists: classification, drug safety, and effectiveness. GI, Gastrointestinal; GLP-1R, Glucagon-like peptide-1 receptor; PEG, Polyethylene glycol. *Liraglutide and Semaglutide have been approved by the United States Food and Drug Administration for weight loss.
Scheme 1 A schematic overview of GLP-1 receptor agonists: classification, drug safety, and effectiveness. GI, Gastrointestinal; GLP-1R, Glucagon-like peptide-1 receptor; PEG, Polyethylene glycol. *Liraglutide and Semaglutide have been approved by the United States Food and Drug Administration for weight loss.CC BY · PubMed Central
Figure 1 The possible mechanisms of weight loss caused by GLP-1. GI, Gastrointestinal; GLP-1, Glucagon-like peptide-1; GLP-1R, Glucagon-like peptide-1 receptor. Created with BioRender.com.
Figure 1 The possible mechanisms of weight loss caused by GLP-1. GI, Gastrointestinal; GLP-1, Glucagon-like peptide-1; GLP-1R, Glucagon-like peptide-1 receptor. Created with BioRender.com.CC BY · PubMed Central

Verification

Claims the paper makes

8 Valid · 3 Not valid · 86 Not checked · 9 Own results and interpretations

32 more claims

Create a free account to see all 106 claims and to verify the 119 references still open.

See all claims — free account
  • It may state two separate claims as one. 63
  • Probably not a substantial claim. 12

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 143 references

Research works printed but not linked: 2

  1. Leon, 2017, Lixisenatide (Adlyxin), Pharm Ther, 42, 676
  2. Knudsen, 1999, Derivatives of glucagon-like peptide-1 suitable for once daily administration, Diabetes, 48

Cited by

See all 264

Metadata

Authors
Wang, J.-Y., Wang, Q.-W., Yang, X.-Y., Yang, W., Li, D.-R., Jin, J.-Y., Zhang, H.-C., & Zhang, X.-F.
Affiliations
First Hospital of Jilin University (CN)
Venue
Frontiers in Endocrinology
Published
2023-02-01
Volume
14
Pages
1085799-1085799
ISSN
1664-2392 (ISSN-L)
OpenAlex
W4319808936
Cited by
248
References
145
Citations by year
2026: 56 · 2025: 86 · 2024: 88 · 2023: 18
FWCI
9.01
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Endocrinology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Natural Science Foundation of China
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
GLP-1 receptor agonists, obesity treatment, incretins, anti-obesity drugs, weight loss, obesity complications, obesity pharmacotherapy
MeSH terms
Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Animals, Obesity, Weight Loss, Anti-Obesity Agents, Incretins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-04, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-04 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach. https://app.cochat.ai/papers/10.3389/fendo.2023.1085799
The paper
Wang, J.-Y., Wang, Q.-W., Yang, X.-Y., Yang, W., Li, D.-R., Jin, J.-Y., Zhang, H.-C., & Zhang, X.-F. (2023). GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach. Frontiers in Endocrinology. https://doi.org/10.3389/fendo.2023.1085799

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.